Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia

Immunology Letters

Volumn 172, Issue , 2016, Pages 113-123

  Sikaria, Swati ^a   Aldoss, Ibrahim ^b   Akhtari, Mojtaba ^a  

^a USC UNIVERSITY HOSPITAL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Immunotherapy; Leukemia; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; BLINATUMOMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD52 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; DENINTUZUMAB; EPRATUZUMAB; INOTUZUMAB OZOGAMICIN; OFATUMUMAB; RITUXIMAB; BISPECIFIC ANTIBODY; CANCER VACCINE; DIFFERENTIATION ANTIGEN; IMMUNOTOXIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACIDOSIS; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTIGEN EXPRESSION; BRAIN DISEASE; CANCER IMMUNOTHERAPY; CELL THERAPY; CLINICAL EFFECTIVENESS; CONSTIPATION; CORNEA DISEASE; CYTOKINE RELEASE SYNDROME; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; LEUKOPENIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PATIENT SAFETY; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREMOR; ADULT; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PRE B LYMPHOCYTE; PROCEDURES; PROTEIN ENGINEERING; T LYMPHOCYTE; TRANSPLANTATION;

ADULT; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RITUXIMAB; T-LYMPHOCYTES;

EID: 84960408565     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.02.014     Document Type: Review

References (60)

1. Farber S., et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N. Engl. J. Med. 1948, 238:787-793.
2. Rowe J.M., Buck G., Burnett A.K., Chopra R., Wiernik P.H., et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005, 106(12):3760-3767.
3. Fielding A.K., Richards S.M., Chopra R., Lazarus H.M., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109(3):944-950.
4. Möricke A., Reiter A., Zimmermann M., et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008, 111(May (9)):4477-4489.
5. Moghrabi A., Levy D.E., Asselin B., Barr R., Clavell L., Hurwitz C., Samson Y., Schorin M., Dalton V.K., Lipshultz S.E., Neuberg D.S., Gelber R.D., Cohen H.J., Sallan S.E., Silverman L.B. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007, 109(February (3)):896-904.
6. Larson R.A., Dodge R.K., Burns C.P., Lee E.J., Stone R.M., Schulman P., Duggan D., Davey F.R., Sobol R.E., Frankel S.R., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995, 85(April (8)):2025-2037.
7. Douer Dan Will novel agents for ALL finally change the natural history?. Best Pract. Clin. Haematol. 2014, 27(3-4):247-258.
8. Behrens C.B., Liu B. Methods for site-specific drug conjugation to antibodies. mAbs 2014, 6(January-February (1)):46-53.
9. Weiland J., Elder A., Forster V., et al. CD19: a multifunctional immunological target molecule and its implications for B lineage acute lymphoblastic leukemia. Pediatr. Blood Cancer 2015, 62:1144-1148.
10. Thomas D.A., O'Brien S., Jorgensen J.L., et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009, 113:6330-6337.
11. Santos L., Draves K., Boton M., et al. Dendritic cell-dependent inhibition of B cell proliferation requires CD22. J. Immunol. 2008, 180(7):4561-4569.
12. Domagała A., Kurpisz M. CD52 antigen-a review. Med. Sci. Monit. 2001, 7(2):325-331.
13. Raponi S., De Propris M.S., Intoppa S., Milani M.L., et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 2011, 52(6):1098-1107.
14. Shah N.N., Stevenson M.S., Yuan C.M., et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr. Blood Cancer 2015, 62:964-969.
15. Ginaldi L., De Martinis M., Matutes E., Farahat N., et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. 1998, 22(2):185-191.
16. Hoelzer D. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 2014, 124(26):3870-3879.
17. Kumar J.J., Khan A.A., et al. Expression of CD20 in B cell precursor acute lymphoblastic leukemia. Indian J. Hematol. Blood Transfus. 2014, 30(1):16-18.
18. Raponi S., et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 2011, 52(6):1098-1107.
19. Thomas D.A., et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. JCO 2010, 28(24):3880-3889.
20. Sébastien, et al., Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study, ASH Plenary (2005).
21. Teeling J.L., Mackus W.J., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 177:362-371.
22. Du J., et al. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol. Immunol. 2009, 46(11-12):2419-2423.
23. Wierda W.G., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. JCO 2010, 28(10):1749-1755.
24. Jabbour E., Kantarjian H., Thomas D., et al. Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL). Blood 2013, 122(21):2664.
25. A.T. Fathi, R. Chen, T.M. Trippett, et al., Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SG N-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma, (ASH Abstract 2014).
26. Offner S., Hofmeister R., Romaniuk A., et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 2006, 43:763-771.
27. Löffler A., Kufer P., Lutterbu se R., et al. A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95:2098-2103.
28. Klinger M., Brandl C., Zugmaier G., Hijazi Y., Bargou R.C., Topp M.S., Gökbuget N., Neumann S., Goebeler M., Viardot A., Stelljes M., Brüggemann M., Hoelzer D., Degenhard E., Nagorsen D., Baeuerle P.A., Wolf A., Kufer P. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012, 119(June (26)):6226-6233.
29. Topp M.S., Kufer P., Gökbuget N., et al. Targeted therapy with the T-cell-engaging antibody Blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 2011, 53(29):2493-2498.
30. Topp M.S., Gokbuget N., Zugmaier G., Klappers P., et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. JCO 2014, 32(36):4134-4140.
31. Topp M.S., Gökbuget N., Stein A.S., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015, 16(January (1)):57-66.
32. Kantarjian H., et al. Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study. J. Clin. Oncol. 2015, 33. (suppl; abstr 7057).
33. N. Gökbuget, H. Dombret, et al., long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL), ASH Abstract (2015).
34. Martinelli, et al., Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA), ASH Abstract (2015).
35. Brentjens R.J., Santos E., Nikhamin Y., Yeh R., Matsushita M., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 2007, 13:5426-5435.
36. Davila M.L., Kloss C.C., Gunset G., Sadelain M. CD19CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 2013, 8(4):e61338.
37. Maude S.L., Frey N., Shaw P.A., Aplenc R., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NEJM 2014, 371:1507-1517.
38. Lee D.W., Kochenderfer J.N., Stetler-Stevenson M., Cui Y.K., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015, 385(9967):517-528.
39. Davila M.L., et al. Efficacy and toxicity management of 19-28z CAR t cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6(224):1-10. (224ra25).
40. R.A. Gardner, et al., T Cell Products of Defined CD4:CD8Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse, ASH Abstract (2014).
41. Cruz C.R., Micklethwaite K.P., Savoldo B., Ramos C.A., Lam S., Ku S., et al. Infusion of donor-derived C-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013, 122(October (17)):2965-2973.
42. de Vries J.F., Zwaan C.M., De Bie M., et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012, 26(2):255-264.
43. DiJoseph J.F., Armellino D.C., Boghaert E.R., et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004, 103(March (5)):1807-1814.
44. DiJoseph J.F., Popplewell A., Tickle S., et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol. Immunother. 2005, 54(January (1)):11-24.
45. DiJoseph J.F., Dougher M.M., Kalyandrug L.B., et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin. Cancer Res. 2006, 12(1):242-249.
46. Advani A., Coiffier B., Czuczman M.S., et al. Safety, pharmacokinetics, and preliminary clinical activity of Inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol. 2010, 28(12):2085-2093.
47. Kantarjian H., Thomas D., Jorgensen J., Jabbour E., Kebriaei P., Rytting M., York S., Ravandi F., Kwari M., Faderl S., Rios M.B., Cortes J., Fayad L., Tarnai R., Wang S.A., Champlin R., Advani A., O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012, 13(April (4)):403-411.
48. Ogura M., Hatake K., Ando K., et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012, 103(5):933-938.
49. Kantarjian H., Thomas D., Jorgensen J., et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013, 119(15):2728-2736.
50. Jabbour E., O'Brien S., Nitin J., et al. Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients and as salvage therapy for adult with R/R acute lymphoblastic leukemia [abstract]. J. Clin. Oncol. 2014, 32(5s). (suppl; abstr 7019). http://meetinglibrary.asco.org/content/132022-144.
51. E. Jabbour, S. O'Brien, D.A. Thomas, et al., Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL) [abstract], ASH (2014).
52. Raetz E.A., Cairo M.S., Borowitz M.J., et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children's oncology group pilot study. J. Clin. Oncol. 2008, 26(22):3756-3762.
53. Raetz E.A., Cairo M.S., Borowitz M.J., Lu X., et al. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr. Blood Cancer 2015, 62(7):1171-1175.
54. Chevallier P., Huguet F., Raffoux E., et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica 2015, 100(4):e128-e131.
55. Advani A., McDonough S., Coutre S., et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia. Brit. J. Haematol. 2014, 165:504-509.
56. Tibes R., Keating M.J., Ferrajoli A., Wierda W., et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006, 106(12):2645-2651.
57. Nijmeijer B.A., van Schie M.L., Halkes C.J., Griffioen M., Will-emze R., Falkenburg J.H. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. Blood 2010, 116:5930-5940.
58. Angiolillo A.L., Yu A.L., Reaman G., Ingle A.M., Secola R., Adamson P.C. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr. Blood Cancer 2009, 53(6):978-983.
59. Stock W., Sanford B., Lozanski G. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a cancer and leukemia group B study (CALGB 10102). Bloo 2009, 114. (ASH Annual Meeting Abstracts) Abstract 838.
60. Gorin N.C., Isnard F., Garderet L., Ikhlef S., Corm S., et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur. J. Haematol. 2013, 91(4):315-321.